MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/jog.15784

Медицинская библиотека · The journal of obstetrics and gynaecology research · 2023

Are HPV-negative lesions concerned for the introduction of primary HPV testing for cervical cancer screening in Japan?

Hideshima Misako, Hashiguchi Mariko, Honda Atsuko, Umezaki Yasushi, Okuma Ryoichi, Hikari Takako, Fukuda Asako, Okugawa Kaoru, Yokoyama Masatoshi

СтатьяПеревод в очереди

Аннотация

AIM: In Japan, primary human papilloma virus (HPV) testing has not been introduced for cervical cancer screening due to concerns that HPV-negative lesions may be missed and a lack of Japanese data. The purpose of this study was to evaluate the validity of primary HPV testing in Japan by analyzing cervical intraepithelial neoplasia 2 (CIN2) or more/high-risk HPV- (CIN2+/hrHPV-) cases in cervical cancer screening.

METHODS

Data from 35 525 cervical cancer screenings with HPV testing and cervical cytology from 2011 to 2019 in Saga City, Japan, were reviewed. The cases with low-grade squamous intraepithelial lesion (LSIL+)/hrHPV- were analyzed in detail.

RESULTS

The results of the 35 525 examinees were as follows: 31 123 were negative for intraepithelial lesion or malignancy (NILM)/hrHPV-, 2612 were NILM/hrHPV+, 262 were atypical squamous cells of undetermined significance (ASC-US)/hrHPV-, 213 were ASC-US/hrHPV+, 291 were LSIL+/hrHPV-, and 1024 were LSIL+/hrHPV+. Of the 256 LSIL+/hrHPV- examinees for whom histology was available, CIN2+ were CIN2 9.4% (24/256), CIN3 3.9% (10/256), cervical adenocarcinoma 0.4% (1/256), uterine corpus cancer 1.2% (3/256), and uterine sarcoma 0.4% (1/256). Overall, the rate of LSIL+/hrHPV- was 0.82% (291/35.525), 0.1% (36/35525) of which were cervical lesions with CIN2+. Only one cervical adenocarcinoma was detected, but gastric-type adenocarcinoma was not included.

CONCLUSION

HPV-negative CIN2+ or cervical adenocarcinoma is not a concern for the introduction of primary HPV screening in Japan. Primary HPV testing in cervical cancer screening is considered a feasible method that can be used in Japan, although an algorithm suitable for Japan and a national-level management system need to be established.

Для цитирования: Hideshima Misako, Hashiguchi Mariko, Honda Atsuko, Umezaki Yasushi, Okuma Ryoichi, Hikari Takako, Fukuda Asako, Okugawa Kaoru, Yokoyama Masatoshi. Are HPV-negative lesions concerned for the introduction of primary HPV testing for cervical cancer screening in Japan?. The journal of obstetrics and gynaecology research. 2023. DOI: 10.1111/jog.15784.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.